Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc. (now Ionis Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Isis is a biopharmaceutical company focused on the discovery and development of antisense drugs. The company utilizes a "partner-centric" strategy, discovering drugs and licensing them to pharmaceutical partners (e.g., Genzyme, Bristol-Myers Squibb) or satellite companies for late-stage development and commercialization. Key therapeutic areas include cardiovascular, metabolic, neurodegenerative diseases, and cancer.
Key Financial Metrics
| Metric (in thousands) | 2009 | 2008 |
|---|---|---|
| Total Revenue | $121,600 | $107,190 |
| Research & Development Expenses | $134,623 | $106,439 |
| General & Administrative Expenses | $14,515 | $13,811 |
| Net Loss from Continuing Operations | $(30,562) | $(9,785) |
| Net Income from Discontinued Operations | $185,628 | $(8,387) |
| Net Income (Loss) Attributable to Stockholders | $155,066 | $(18,172) |
| Cash, Cash Equivalents & Short-term Investments | $574,312 | $490,998 |
| Working Capital | $484,682 | $393,685 |
| Long-term Debt & Obligations | $243,675 | $300,697 |
Note: 2009 Net Income is significantly impacted by the sale of the Ibis Biosciences subsidiary (Discontinued Operations).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13.5% to $121.6 million, driven primarily by increased amortization of upfront payments from the Genzyme alliance and a $10 million sublicensing fee from OncoGenex (related to the Teva license of OGX-011).
- Operating Expenses: Operating expenses rose 24% to $149.1 million. This increase was due to expanded clinical development programs, specifically the Phase 3 trials for mipomersen (cardiovascular), and increased costs associated with the Regulus Therapeutics subsidiary.
- Discontinued Operations: The company sold its Ibis Biosciences subsidiary to Abbott Molecular Inc. (AMI) in January 2009 for a total purchase price of $215 million. This resulted in a one-time gain of $185.6 million (net of tax), turning a 2008 net loss into a 2009 net income.
- Accounting Changes: The company adopted new accounting standards for convertible debt (FSP APB 14-1) and noncontrolling interests (SFAS 160), resulting in retroactive adjustments to prior periods and increased non-cash interest expense.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Mipomersen (Cardiovascular): The lead drug candidate showed positive Phase 3 data in patients with homozygous and heterozygous familial hypercholesterolemia (FH), meeting primary endpoints for LDL-C reduction. Regulatory filings are expected in the U.S. and E.U. by mid-2011.
- Metabolic Franchise: Positive Phase 2 data reported for ISIS 113715 (PTP-1B inhibitor) in Type 2 diabetes, showing glucose control and weight loss tendencies. Phase 1 data for ISIS-GCGR Rx was also positive.
- Regulus Therapeutics: A new collaboration with GlaxoSmithKline (GSK) was announced in February 2010 to develop microRNA therapeutics for Hepatitis C (miR-122), with potential payments exceeding $150 million.
- Accounting Shift: Beginning in Q1 2010, Regulus Therapeutics will be deconsolidated from Isis's financial statements due to a change in accounting standards. Regulus's revenue and expenses will no longer be included in Isis's operating results; instead, Isis will report its share of Regulus's results as "Equity in loss of Regulus Therapeutics Inc."
Risks and Contingencies
- Clinical Trial Risk: High failure rate in drug development; success in early trials does not guarantee Phase 3 success or regulatory approval.
- Regulatory Risk: FDA requirements for mipomersen may require additional outcome studies for broader indications, potentially delaying commercialization.
- Partnership Dependence: Revenue relies heavily on a few partners (Genzyme accounted for 55% of 2009 revenue). Termination or failure of partners to fund programs could severely impact operations.
- Liquidity: While cash reserves are strong ($574.3 million), the company has a history of losses and may require additional financing if commercialization goals are not met.
- Legal Proceedings: Ongoing litigation with Bruker Daltonics regarding the Ibis T5000 System; no loss has been recorded as the outcome is uncertain.
Key Facts for Investor Verification
- Discontinued Operations Impact: Verify that the 2009 net income of $155 million is primarily driven by the $185.6 million gain from the Ibis sale, not core operating profitability (which remained a loss of $30.6 million).
- Regulus Deconsolidation: Confirm the impact of the Q1 2010 accounting change on future revenue recognition and expense reporting regarding the Regulus subsidiary.
- Mipomersen Timeline: Monitor the progress of the remaining Phase 3 studies and the anticipated regulatory filing dates (mid-2011) for the lead cardiovascular asset.
- Deferred Revenue: Review the significant deferred revenue balance ($160.4 million related to Genzyme) and the amortization schedule, as this drives future revenue stability.
- Convertible Debt: Note the $162.5 million in 2 5/8% convertible subordinated notes due in 2027 and the associated non-cash interest expense resulting from the new accounting standard.